CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net (loss) income before equity in losses of unconsolidated affiliates	$ (15,668)	$ (594)
Adjustments to reconcile net loss to cash (used in) provided by operating activities:
Depreciation and amortization	10,327	10,084
Non-cash impact of operating leases	2,012	1,582
Deferred tax benefit	(4,625)	(4,043)
Stock-based compensation	12,311	14,861
Change in fair value of contingent consideration	(315)	(744)
Provision for credit losses on convertible note receivable	3,499	0
Equity in losses of unconsolidated affiliates	1,094	837
Accretion of discounts and issuance costs	29	48
Other losses (gains), net	1,233	1,057
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	801	5,504
Inventories	(12,710)	(9,286)
Lease receivables	(5,152)	(3,528)
Other assets	(710)	(3,357)
Accounts payable	268	(2,913)
Other liabilities	(11,045)	(4,236)
Net cash (used in) provided by operating activities	(18,651)	5,272
Cash flows from investing activities:
Promissory note receivable issuance	(4,700)	(9,000)
Purchases of property and equipment	(1,600)	(993)
Proceeds from disposition of property and equipment	0	42
Net cash used in investing activities	(35,256)	(34,596)
Cash flows from financing activities:
Payment of stock issuance costs	0	(314)
Proceeds from issuance of common stock	2,840	168,770
Payments for taxes related to shares withheld for employee taxes	(5,224)	(1,503)
Repayments of other debt	(158)	(821)
Payments on Notes Payable	(2,385)	0
Net cash (used in) provided by financing activities	(4,927)	166,132
Foreign exchange effect on cash and cash equivalents	(3,666)	(242)
Net (decrease) increase in cash and cash equivalents	(62,500)	136,566
Cash and cash equivalents, beginning of period	223,574	86,334
Cash and cash equivalents, end of period	161,074	222,900
Supplemental disclosure of cash flow information:
Non-cash transfers of equipment between inventory and property and equipment, net	2,070	3,678
Contingent consideration for acquisitions	3,860	3,290
Notes payable	0	15,900
Indemnity holdback and net working capital adjustment for acquisitions	1,420	346
Lacuna Diagnostics, Inc.
Cash flows from investing activities:
Acquisition	0	(3,882)
VetZ GmbH
Cash flows from investing activities:
Acquisition	(28,956)	0
Biotech
Cash flows from investing activities:
Acquisition	0	(16,250)
Cash flows from financing activities:
Payments on Notes Payable	(2,600)
BiEsseA s.r.1.
Cash flows from investing activities:
Acquisition	$ 0	$ (4,513)